Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) was a big mover last session, as the company saw its shares rise by roughly 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 30% in the past one-month time frame.Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares after opening at $16.88 moved to $17.36 on last trade day and at the end of the day closed at $15.07. Company price to sales ratio in past twelve months was calculated as 14.89 and price to cash ratio as 3.87. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) showed a negative weekly performance of -5.46%.
Halozyme Therapeutics, Inc. (HALO) announced this morning that its phase 2 trial enrollment and dosing for PEGPH20 has come to a halt, driving its stock price down more than 31% in pre-market trading. The stock is trading down 30% as of 1 pm EST. Halozyme Therapeutics, Inc. (NASDAQ:HALO) shares fell -27.26% in last trading session and ended the day on $8.43. HALO its return on assets is -76.60%. Halozyme Therapeutics, Inc. (NASDAQ:HALO) yearly performance is 63.37%.
Oncomed Pharmaceuticals Inc (NASDAQ:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, reported financial results and reviewed corporate events for the year and quarter ended December 31, 2013.2013 was a year of significant accomplishments across all aspects of our business. Our successful initial public offering in July and the signing of a transformational drug development collaboration with Celgene in December significantly strengthened our financial resources and provided further momentum for our scientific approach and progress,” said Paul J. Hastings, Chairman and Chief Executive Officer. “We now have 15 clinical trials currently underway across multiple tumor indications for five distinct anti-cancer stem cell therapeutics, two additional INDs on novel CSC antibodies expected in the next 6-12 months, and a growing pipeline of novel preclinical biologic candidates. We expect this year to be one of continued execution on plan as we advance our portfolio and generate new data. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) shares moved down -13.44% in last trading session and was closed at $26.22, while trading in range of $26.00-$31.98. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) year to date performance is -11.18%.
Shares of Prothena Corp (NASDAQ:PRTA) were the recipient of a large increase in short interest in the month of January. As of March 14th, there was short interest totalling 824,645 shares, an increase of 35.0% from the February 28th total of 610,797 shares, AnalystRatingsNetwork.com reports. Prothena Corporation PLC (NASDAQ:PRTA) weekly performance is -17.85%. On last trading day company shares ended up $29.60. Prothena Corporation PLC (NASDAQ:PRTA) distance from 50-day simple moving average is -12.88%.
Leave a Reply